Thirty-six @entity1 with advanced @entity213 ( @entity213 ) were treated with a regimen including @entity900 (CP) 30 mg/m2 i.v., @entity1487 ( @entity1487 ) 500 mg/m2 i.v. bolus, @entity4181 (FA) 200 mg/m2 i.v. in a continuous one-hour infusion, and @entity1732 (B) 15 mg i.m. on the first and second days and repeated every 28 days. Thirty-three @entity1 (25 with recurrent disease and 8 untreated) are evaluable for objective response. Of these, 4 (12%) achieved CR and 15 (45%) PR. All of the untreated @entity1 responded. The mean duration of response in the @entity1 with recurrent or metastatic disease was 5.5 months (range 2-10+). Remission of symptoms, such as @entity158 and @entity1282 , was obtained in 58% and in 44%, respectively. Subjective remission occurred almost exclusively in objectively responsive @entity1 . The major side effects were @entity1431 (55%) and @entity390 / @entity391 (58%). This regimen is active in the treatment of advanced @entity213 . The quality of life may be improved in responsive @entity1 .

@entity1487 + XXXX with @entity900 and @entity1732 in the treatment of advanced head and @entity213 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['folinic acid'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity213 :: ('MESH:C535575', 'Disease') :: ['squamous cell carcinoma of the head and neck', 'SCCHN'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatinum'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity4181 :: (MESH:D002955,Chemical) :: ['folinic acid']
